These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34212457)

  • 21. Pembrolizumab: first global approval.
    Poole RM
    Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psoriasis Induced by Vedolizumab.
    Sody E; Körber A
    Inflamm Bowel Dis; 2017 Feb; 23(2):E9-E11. PubMed ID: 28107281
    [No Abstract]   [Full Text] [Related]  

  • 23. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secukinumab treatment of tumor necrosis factor antagonists induced paradoxical psoriasis flares in a patient with plaque psoriasis.
    Zheng J; Li Y; Ding Y; Gao Y
    Dermatol Ther; 2020 Nov; 33(6):e14455. PubMed ID: 33107149
    [No Abstract]   [Full Text] [Related]  

  • 26. Pembrolizumab-induced linear psoriasis.
    Huang PW; Chu CY
    Lung Cancer; 2020 Aug; 146():378-379. PubMed ID: 32586659
    [No Abstract]   [Full Text] [Related]  

  • 27. Pembrolizumab for melanoma- safety profile and future trends.
    Daud A; Nandoskar P
    Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
    [No Abstract]   [Full Text] [Related]  

  • 28. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
    Matsumura N; Ohtsuka M; Kikuchi N; Yamamoto T
    Acta Derm Venereol; 2016 Feb; 96(2):259-60. PubMed ID: 26270860
    [No Abstract]   [Full Text] [Related]  

  • 30. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 31. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
    J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
    Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph R; Weber JS; Dronca R; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Zhao Q; Jensen E; Ahsan S; Ibrahim N; Ribas A
    Ann Oncol; 2019 Apr; 30(4):582-588. PubMed ID: 30715153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

  • 34. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
    Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab-induced lobular panniculitis in the setting of metastatic melanoma.
    Peterman CM; Robinson-Bostom L; Paek SY
    Cutis; 2020 Jan; 105(1):E22-E23. PubMed ID: 32074162
    [No Abstract]   [Full Text] [Related]  

  • 37. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis.
    Satoh M; Yamamoto T
    Dermatol Ther; 2020 May; 33(3):e13332. PubMed ID: 32219955
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
    Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA
    Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.